RIPGBM

Key Product Details

Product Description

RIPGBM is a RIPK2 modulator, pro-drug of cRIPGM. cRIPGM binds RIPK2 (apparent K_d = 2.3 μM). Selectively induces apoptosis in glioblastoma multiforme cancer stem cell lines (EC₅₀ is <500 nM). Five-fold selective for CSCs compared with control cell types. Reduces the formation of a prosurvival RIPK2/ TAK1 complex and increases the formation of a proapoptotic RIPK2/caspase 1 complex. Inhibits tumor formation and growth in vivo. Orally bioavailable and brain penetrant.

Product Specifications for RIPGBM

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for RIPGBM

The following data is based on the product molecular weight 428.46.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.1 mM	23.34 mL	116.70 mL	233.39 mL
0.5 mM	4.67 mL	23.34 mL	46.68 mL
1 mM	2.33 mL	11.67 mL	23.34 mL
5 mM	0.47 mL	2.33 mL	4.67 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Lucki A cell type-selective apoptosis-inducing small molecule for the treatment of brain cancer. Proc.Natl.Acad.Sci.USA. 2019 PMID: 30846550

Product Documents for RIPGBM